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2149Synergy Between PCI With TAXUS and Cardiac Surgery trial (7)
and the clear beneﬁt held by coronary artery bypass grafting
over percutaneous coronary intervention, a technique that not only
relieves ischemia but also protects against rupture in all the prox-
imal plaques, which it bypasses. To this end, the results of the
ISCHEMIA (International Study of Comparative Health Effec-
tiveness With Medical and Invasive Approaches) study are keenly
anticipated, although it will be important to assess whether any
beneﬁt relates directly to the reduction of the ischemic burden.*Nikhil V. Joshi, MD
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381:629–38.ReplyIs Ischemia Really Bad for You?
We appreciate the comments of Drs. Joshi and Dweck and agree
with them that our study challenges the concept that inducible
myocardial ischemia is a requisite for determining which patients
with coronary artery disease and left ventricular dysfunction will
beneﬁt from surgical revascularization (1). Although this may not
be surprising, it had never been proved in the context of
a prospective randomized clinical trial. A separate analysis revealed
that the most common mode of death in patients enrolled in the
STICH (Surgical Treatment for Ischemic Heart Failure) trial was
sudden death (2). We have postulated that the dissociation we
observed between myocardial ischemia and prognosis may indicate
that ischemia induced during stress is not causally related to eitherthe risk for plaque rupture or nonischemic ventricular arrhythmias
that may contribute to sudden death.
We also concur regarding the apparent disconnect between the
presence and extent of inducible ischemia during stress testing and
the lack of tangible beneﬁts delivered by therapies (such as percu-
taneous coronary intervention) to relieve ischemia in patients with
stable coronary artery disease. Although the results of our study
cannot be extrapolated to all patients with ischemic heart disease,
including those with normal left ventricular systolic function, they
do defy the long-believed paradigm linking reduction of ischemic
burden and improvement in prognosis.
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LVAD Ramp Test
We would like to add a letter to our paper previously published by
Uriel et al. (1).
We are honored to have been contacted by many centers
nationally and internationally about our ramp test. However, it has
come to our attention that some centers performing the test are
unfortunately having issues analyzing their collected data. To
ensure that such technical issues do not limit the applicability of
the ramp study in clinical decision making, we propose to add
a brief elaboration of our analysis in addition to a downloadable,
pre-formatted Excel spreadsheet.
As we know, left ventricular end-diastolic diameter (LVEDD),
power, and pulsatility index (PI) are expected to change with the
manipulation of a patient’s left ventricular assist device (LVAD)
speed in a well-functioning pump. For our ramp protocol, we start
at 8,000 RPM and increase the LVAD speed by 400-RPM
increments. For our linear ﬁt analysis, each 400-RPM increment
is given a value of 1 “speed change.” Therefore, the values of the
dependent variables (LVEDD, power, and PI) are plotted against
the number of 400-RPM speed changes (i.e., 8,000 ¼ 0; 8,400 ¼
1; 8,800 ¼ 2, and so on). A numerical slope can then be generated
via the Excel function: ¼ slope (dependent variable, number of
speed changes) as seen in Figure 1. For this example, the LVEDD
slope ¼ 0.149.
